追加説明:
Beyfortus (nirsevimab) is a recombinant humanized monoclonal antibody offered by VuRoyal (SuQian) Pharmaceutical Company LLC, which trades rather than manufactures the biologic, in injection grade meeting ChP, USP and EP standards. Developed by AstraZeneca with Sanofi and approved in 2023, it uses YTE technology to target the RSV F protein, providing months of protection from a single injection to prevent severe lower respiratory tract infection in infants and young children; it is distributed across North America and Central/South America.
評価とコメントを残す